Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223480 | 0.84 | MAPT (0.41) | MAPTFAAH | |
| SCHEMBL6867730 | 0.80 | MAPT (0.41) | MAPTFAAH | |
| SCHEMBL1706068 | 0.78 | MAPT (0.41) | MAPTFAAH | |
| SCHEMBL22883299 | 0.77 | MAPT (0.41) | MAPTFAAH | |
| SCHEMBL1445320 | 0.77 | MAPT (0.40) | MAPTFAAH | |
| SCHEMBL7007545 | 0.77 | FAAH (0.44) | MAPTFAAH | |
| SCHEMBL1397078 | 0.74 | MAPT (0.38) | MAPT | |
| SCHEMBL19972943 | 0.74 | FAAH (0.40) | MAPTFAAH | |
| SCHEMBL19972885 | 0.74 | FAAH (0.40) | MAPTFAAH | |
| SCHEMBL28714853 | 0.74 | FAAH (0.40) | MAPTFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020115669-A1 | Oxazolidinone chemotherapeutic agents | ABBOTT LABORATORIES | 2002-08-22 | — | — | US | disclosed |
| WO-2002018354-A1 | OXAZOLIDINONES AND THEIR USE AS ANTIBACTERIAL AGENTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115669-A1 | Oxazolidinone chemotherapeutic agents | TOP1, OXA1L, TK1 | MAPT 2174/4885FAAH 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.